Insmed reports positive data for its Phase 2 product candidate and announces plans to advance to Phase 3 development.
2020
Insmed’s first product is approved in Europe; initial country launches begin.
2021
Insmed initiates clinical program to evaluate first approved product in the frontline setting.
2021
Insmed reports positive Phase 1 data for its earlier-stage product candidate in healthy volunteers.
2021
Insmed’s first product is approved and launches in Japan.
2021-2022
Insmed establishes new Research facilities in New Hampshire and San Diego to support the evolution of its fourth pillar.